Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01049230 · ClinicalTrials.gov registry record · NA
Proton Beam Radiation Therapy for Central Nervous System (CNS) Germ Cell Tumors
A NA study of Germ Cell Tumor and Central Nervous System Germ Cell Tumor, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 2
- Study locations
NCT01049230: Active NA study of Germ Cell Tumor and Central Nervous System Germ Cell Tumor, sponsored by Massachusetts General Hospital.
NCT01049230 is a NA study of Germ Cell Tumor and Central Nervous System Germ Cell Tumor that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 45 participants, below the 345-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (87% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01049230, a NA study of Germ Cell Tumor and Central Nervous System Germ Cell Tumor, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this research study is to determine if radiation using proton beam therapy will kill the germ cell tumor in the participant's central nervous system. This type of radiation has been used previously on many patients with different types of cancers. There are two types of external radiation treatments, proton beam and photon beam. In this study we will be examining the effects of proton beam radiation therapy. Studies have suggested that this kind of radiation can spare normal tissue more than photon radiation therapy. The physical characteristics of proton beam radiation let the doctor safely increase the amount of radiation delivered to the tumor. We believe that proton beam therapy will potentially reduce side effects that participants would normally experience with photon radiation therapy.
Conditions Studied
Interventions
- RADIATION Proton Beam radiation
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2010-06 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
What the registry record for NCT01049230 still lists
NCT01049230 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 345-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with Germ Cell Tumor appearing as the primary indexed condition, and to 1 intervention - of which Proton Beam radiation is the first listed.
NCT01049230 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01049230 about?
NCT01049230 is a clinical study titled "Proton Beam Radiation Therapy for Central Nervous System (CNS) Germ Cell Tumors". The purpose of this research study is to determine if radiation using proton beam therapy will kill the germ cell tumor in the participant's central nervous system. This type of radiation has been used previously on many patients with different types of cancers. There are two types of external radia...
What is the current status of trial NCT01049230?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 45 participants. The study started on 2010-06. Estimated completion is 2027-12-31.
What conditions does trial NCT01049230 study?
This clinical trial studies the following conditions: Germ Cell Tumor, Central Nervous System Germ Cell Tumor.
What interventions are being tested in trial NCT01049230?
The interventions under investigation include: Proton Beam radiation (RADIATION).
Who is sponsoring clinical trial NCT01049230?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01049230 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Germ Cell Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01049230's enrollment target sits among peer trials
45 12th of 19 higher than 8 of 19 other Germ Cell Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Germ Cell Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
RECRUITING · Phase 1
-
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
RECRUITING · Phase 3
-
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
RECRUITING · Phase 3
-
Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT
RECRUITING · Phase 2
-
Germ Cell Tumor and Testicular Tumor DNA Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia